UroAlert - GU Oncology Weekly

November 27, 2024

Videos

Peer-to-Peer Clinical Conversations

Nectin-4 Expression Not Predictive of Response in Enfortumab Vedotin Therapy - Thomas Powles

Thomas Powles

Thomas Powles discusses an exploratory nectin-4 biomarker analysis from the EV-302 trial.

Radium-223 Plus Enzalutamide Improves Survival in mCRPC: PEACE-3 Trial Results, Journal Club - Rashid Sayyid & Zachary Klaassen

Zachary Klaassen

Rashid Sayyid and Zachary Klaassen discuss the resurgence of radium-223 in treating metastatic castration-resistant prostate cancer (mCRPC), focusing on the PEACE-3 trial results.

Beyond the Abstracts

Modulation of the Tumor Microenvironment in Non-Muscle-Invasive Bladder Cancer by OncoTherad® (MRB-CFI-1) Nanoimmunotherapy: Effects on Tumor-Associated Macrophages, Tumor-Infiltrating Lymphocytes, and Monoamine Oxidases - Beyond the Abstract

Patient Preferences for Attributes of Androgen Deprivation Therapies in Prostate Cancer: A Discrete Choice Experiment with Latent Class Analysis - Beyond the Abstract

Conference Coverage

SCS AUA 2024: Does the Use of Continuous Bladder Irrigation After TURBT Increase the Risk of Complications?

SCS AUA 2024: Should Veterans be Classified as High Risk for Prostate Cancer Screening: A Review of the Current Literature

SCS AUA 2024: Can the PSMA PET SUVmax Predict High Risk Pathology and High Risk Disease? A Single Center Prospective Disease

SCS AUA 2024: Elucidating the Response Rates to Additional BCG: Implications for Clinical Trial Design

SCS AUA 2024: Can We Predict Locally Advanced Disease Features with PSMA PET? Correlation of Molecular Imaging TNM with Pathological TNM in Radical Prostatectomy Specimen

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Muscle-Invasive Bladder Cancer in Non-Curative Patients: A Study on Survival and Palliative Care Needs - Beyond the Abstract

Proteomic analysis of non-muscle invasive and muscle invasive bladder cancer highlights distinct subgroups with metabolic, matrisomal, and immune hallmarks and emphasizes importance of the stromal compartment.

Concomitant Chemotherapy in Trimodal Treatment of Patients with Muscle Invasive Bladder Cancer: A Systematic Review of Prospective Trials.

Efficacy of Inpatient, Evidence-Based Tobacco Use Treatment of Patients With Bladder Cancer After Radical Cystectomy.

Penoscrotal Extension and Fistulation From Urothelial Carcinoma of the Bladder

Trimodality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Matched Cohort Studies.

State of the Art: The Microbiome in Bladder Cancer.

French AFU Cancer Committee Guidelines - Update 2024-2026: Muscle-invasive bladder cancer (MIBC).

French AFU Cancer Committee Guidelines - Update 2024-2026: Non-muscle invasive bladder cancer (NMIBC).

Understanding the long-term impact of the COVID-19 pandemic on non-muscle-invasive bladder cancer outcomes: 12-Month follow-up data from the international, prospective COVIDSurg Cancer study.

Comparative analysis of oncological outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer utilizing propensity score matching.

Metastasis development in non-muscle-invasive bladder cancer.

Uromonitor®: Clinical Validation and Performance Assessment of a Urinary Biomarker within the Surveillance of Non-Muscle Invasive Bladder Cancer Patients.

Artificial Intelligence can Facilitate Application of Risk Stratification Algorithms to Bladder Cancer Patient Case Scenarios.

A Novel Gene Expression Scoring System Predicts Recurrence in Non-Muscle-Invasive Bladder Cancer Patients.

Efficacy and Safety of an Avelumab and Chemotherapy Combination Treatment Regimen in Cisplatin Ineligible Patients with Metastatic Urothelial Carcinoma - Expert Commentary

Perioperative Platform for Muscle-Invasive Bladder Cancer Trials: Designs and Endpoints - Beyond the Abstract

Perioperative Complications and In-Hospital Mortality in Paraplegic Radical Cystectomy Patients - Beyond the Abstract

Penile & Urethral Cancers

French AFU Cancer Committee Guidelines-Update 2024-2026: Penile cancer.

Partial penectomy with reconstruction using a split-thickness skin graft: a multicenter experience.

Renal Cancer

Papillary renal cell carcinoma revisited: impact of the World Health Organization 2022 classification on prognostication.

Real-world outcomes of avelumab plus axitinib in patients with advanced renal cell carcinoma in Japan: long-term follow-up from the J-DART2 retrospective study.

Association between the systemic inflammation response index and kidney stones in US adults: a cross-sectional study based on NHANES 2007-2018.

Synchronized autologous T-cell immunotherapy with hyperthermia to previously heavy treated advanced renal cell carcinoma.

French AFU Cancer Committee Guidelines - Update 2024-2026: Management of kidney cancer.

Robot-assisted partial nephrectomy vs. percutaneous cryoablation for T1a renal tumors: a single-center retrospective analysis of outcomes and costs.

Risk factors for kidney cancer and socio-occupational category: significant impact of chlorinated solvents (UroCCR 111).

CD70: An Emerging Anticancer Target in Renal Cell Carcinoma and Beyond.

Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis.

Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma.

Adjuvant therapy for renal cell carcinoma : Relevant patient and tumor factors.

The Impact of Concomitant Medications on the Overall Survival of Patients Treated with Systemic Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis.

Prostate Cancer

Impact of TP53 Loss-of-Function Alterations on the Response to PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients - Beyond the Abstract

Multimodal approach to optimize biopsy decision-making for PI-RADS 3 lesions on multiparametric MRI.

Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.

Prostate Image Quality System (PI-QUAL) Version 2 - A Practical Guide.

Clinical characteristics and treatment of patients with small cell prostate cancer: analysis of a real-world cohort from an oncology database.

The role of Cabazitaxel in Patients With Castration-Resistant and Osseous Metastases Prostate Cancer. A Hellenic Cooperative Oncology Group Phase II Study: Cabazitaxel in mCRPC patients with osseous metastases.

Elucidating acquired PARP inhibitor resistance in advanced prostate cancer.

Dynamics in the Prostate Immune Microenvironment Induced by Androgen Deprivation Therapy.

Role of Chemokines and Cytokines in Prostate Cancer Skeletal Metastasis.

Discrimination against Gay and Bisexual Patients in Prostate Cancer Treatment: Results from the Restore-2 Study.

Prioritizing precision: detection of prostate cancer using mri guided fusion needle biopsy across the pennsylvania urologic regional collaborative.

French AFU Cancer Committee Guidelines - Update 2024-2026: Prostate cancer - Management of metastatic disease and castration resistance.

French AFU Cancer Committee Guidelines - Update 2024-2026: Prostate cancer - Diagnosis and management of localised disease.

Influences on androgen deprivation therapy prescribing before surgery in high-risk prostate cancer.

Cost-effectiveness analysis of additional local prostate radio therapy in metastatic prostate cancer from a medicare perspective.

Central Nervous System Toxicity in Prostate Cancer Patients Treated with Androgen Receptor Signaling Inhibitors: A Systematic Review, Meta-analysis, and Network Meta-analysis.

Association of Race and Area of Deprivation Index with Prostate Cancer Incidence and Lethality.

Organ-confined prostate cancer with negative surgical margins in an entirely-embedded radical prostatectomy is essentially non-lethal-a retrospective single-institutional study of 520 patients.

PSMA Radiotheranostics in Prostate Cancer: Principles, Practice, and Future Prospects.

Evaluation of ChatGPT as a Reliable Source of Medical Information on Prostate Cancer for Patients: Global Comparative Survey of Medical Oncologists and Urologists.

Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer.

Unmasking Neuroendocrine Prostate Cancer with a Machine Learning-Driven Seven-Gene Stemness Signature That Predicts Progression.

Germline sequencing in men with metastatic castration-resistant prostate cancer from the BARCODE2 study reveals a wide range of pathogenic variants in DNA repair genes.

A PSMA-targeted Tri-specific Killer Engager enhances NK cell cytotoxicity against prostate cancer.

Racial and Ethnic Differences in Prostate Cancer Epidemiology Across Disease States in the VA.

Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in mice.

Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer.

Using a behaviour-change approach to support uptake of population genomic screening and management options for breast or prostate cancer.

Tumor architecture and emergence of strong genetic alterations are bottlenecks for clonal evolution in primary prostate cancer.

Long-Term Adverse Effects and Complications After Prostate Cancer Treatment.

Association of Free-to-Total PSA Ratio and 18F-DCFPyL Prostate-Specific Membrane Antigen PET/CT Findings in Patients with Biochemical Recurrence After Radical Prostatectomy: A Prospective Single-Center Study.

Sclerotic prostate cancer bone metastasis: woven bone lesions with a twist.

Automated real-world data integration improves cancer outcome prediction.

Patients Can Administer Mobile Audio Recordings to Increase Knowledge in Advanced Prostate Cancer.

Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer.

The Association of Where Patients with Prostate Cancer Live and Receive Care on Racial Treatment Inequities.

Projected Outcomes of Reduced-Biopsy Management of Grade Group 1 Prostate Cancer: Implications for Relabeling.

Integrated framework for quantitative T2-weighted MRI analysis following prostate cancer radiotherapy.

Anatomic Factors Associated with Complications After Radical Prostatectomy: A Systematic Review and Meta-analysis.

Repeat Prostate Cancer Screening using Blood-based Risk Prediction or Prostate-specific Antigen in the Era of Magnetic Resonance Imaging-guided Biopsies : A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial.

Prostate Cancer Screening: Common Questions and Answers.

Comparing the Technological and Intraoperative Performances of Da Vinci xi and DaVinci 5 Robotic Platforms in Patients Undergoing Robotic-Assisted Radical Prostatectomy.

Preoperative prostate magnetic resonance imaging does not impact surgical outcomes of radical prostatectomy.

Patient Preferences for Attributes of Androgen Deprivation Therapies in Prostate Cancer: A Discrete Choice Experiment with Latent Class Analysis - Beyond the Abstract

Evaluating 4Kscore's Role in Predicting Progression on Active Surveillance for Prostate Cancer Independently of Clinical Information and PIRADS Score - Beyond the Abstract

CDK12 Loss Drives Prostate Cancer Progression, Transcription-Replication Conflicts, and Synthetic Lethality with Paralog CDK13 - Beyond the Abstract

CRPC w/ bone metastases

Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT/CT with xSPECT Quant: prospective imaging sub-study of a phase 2 clinical trial investigating the combination of pembrolizumab plus radium-223 compare

Upper Tract Tumors

New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma (LG UTUC) with UGN-101, A Mitomycin Reverse Thermal Gel

French AFU Cancer Committee Guidelines - Update 2024-2026: Upper urinary tract urothelial cancer (UTUC).

Testicular Cancer

French AFU Cancer Committee Guidelines - Update 2024-2026: Testicular germ cell cancer.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2024 Digital Science Press, LLC